Pharmaceutical Technology

MAY 31, 2023

In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases. The agreement will cover the Hong Kong special administrative region (SAR), the Macau SAR and Taiwan.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Pharmaceutical Technology

MAY 10, 2023

CytoMed Therapeutics has signed a research collaboration deal with the University of Texas MD Anderson Cancer Center (MD Anderson) in the US to use gamma-delta T cells (gdTc) to treat acute myeloid leukaemia (AML) and breast cancer. MD Anderson leukaemia associate professor Venkata Lokesh Battula will lead the research study.

Gene Therapy 147

Gene Therapy In-Vivo In-Vitro Gene 147

Pharmaceutical Technology

SEPTEMBER 10, 2008

was established in 1999 in the process of privatisation of the State Research Institute for Pharmacy and Biochemistry in the Czech Republic. ” New projects we have been involved with have helped the company to accelerate its development in the field of pre-clinical research. Dr Ivana Surovà: Biotest s.r.o.

In-Vitro 100

In-Vitro Genotoxicity In-Vivo Development 100

pharmaphorum

FEBRUARY 19, 2021

Khalili said: “This transformative financing will accelerate and support the research we have developed over the past decade. Khalili said: “This transformative financing will accelerate and support the research we have developed over the past decade. “We The post Could CRISPR cure HIV?

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

pharmaphorum

FEBRUARY 13, 2022

Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity.

Drugs 98

Drugs In-Vivo In-Vitro Pharma Companies 98

XTalks

DECEMBER 13, 2024

XTALKS WEBINAR: Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data Live and On-Demand: Thursday, January 16, 2025, at 11am EST (4pm GMT/UK) Register for this free webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

Antibody 99

Antibody In-Vivo Trials In-Vitro 99

BioTech 365

MARCH 9, 2021

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Scientists discover dynamic trimolecular G-quadruplex.As

Scientist 40

Scientist In-Vivo In-Vitro DNA 40

The Pharma Data

MAY 3, 2021

In 2019, the division conducted a clinical trial to quantify the systemic absorption of sunscreen ingredients and has since published additional research on the topic. . Overall, the division’s cardiac safety research program yielded 25 publications and three FDA-sponsored clinical trials to assess cardiac safety biomarkers.

In-Vitro 52

In-Vitro Clinical Trials Clinical Trials In-Vivo 52

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

pharmaphorum

JANUARY 25, 2022

For example, there is no need for in vivo animal or in vitro pre-clinical or non-clinical studies. The area of digital therapeutics is growing rapidly, and in this piece Ben Hargreaves examines why this is the case, how broadly these therapies can be applied and why investment in the area is mounting. This equated to $21.3

Medicine 111

Medicine In-Vivo In-Vitro Development 111

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. The pandemic proved that mRNA technology could provide effective protection against infectious disease, at least in the case of COVID-19.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. A solution could be at hand with Overland Pharmaceuticals. Below is a roundup of some of this week’s interesting news.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

JUNE 17, 2022

Researchers from the Institut Pasteur, Université Paris Cité, and INSERM examined 102 SARS-CoV-2 spike monoclonal antibodies cloned from the B cells of 10 COVID-19 convalescents. The research has its roots in a task force launched by the Institut Pasteur in the early days of the COVID-19 pandemic.

Antibody 52

Antibody In-Vivo In-Vitro Immune Response 52

The Pharma Data

JANUARY 4, 2021

ViGeneron’s recognized expertise in retinal gene therapy together with Biogen’s leading research, drug development and commercialization experience is a powerful combination that we believe will allow us to deliver more novel gene therapies to patients in need.”. The companies will work together on the in vivo proof of concept (POC).

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

The Pharma Data

JANUARY 6, 2021

The research collaboration is aimed at identifying novel lead compounds and repurposing existing drugs for rheumatoid arthritis and nonalcoholic steatohepatitis, leveraging Standigm’s AI-powered drug discovery platforms : Standigm BEST , Standigm Insight , and Standigm ASK. About Standigm. Standigm is an AI-driven drug discovery company.

FDA Approval 52

FDA Approval Life Science Drugs In-Vivo 52

FDA Law Blog

FEBRUARY 2, 2023

The law defines this term to mean “a test conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug.” Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 262(k)(2)(A)(i)(I).

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

The Pharma Data

MARCH 29, 2022

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

MARCH 25, 2022

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 7,8) This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.(7).

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

The Pharma Data

JANUARY 19, 2021

a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel pharmacotherapy: NNI-362 to allosterically stimulate neural regeneration in human cultures and in vivo models of aging and disease. CLARKSVILLE, Md., 20, 2021 (GLOBE NEWSWIRE) — Neuronascent Inc. , About NNI-362.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials In-Vitro 40

Delveinsight

DECEMBER 21, 2020

Research has shown that most of the cannabinoids bind to G-protein coupled cannabinoid receptors, CB1 and CB2, and act as agonists or inverse agonists. The expressions of these receptors were detected in GBM cell lines – in ex-vivo primary cancer cells extracted and in-situ GBM tissue biopsies. What causes cancer to relapse?

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials In-Vitro 52

XTalks

SEPTEMBER 20, 2024

XTALKS CLINICAL EDGE: Issue 3 — Interview with CTTI Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. Such challenges highlight a significant unmet need and call for further advancements in the field.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

The Pharma Data

DECEMBER 9, 2020

Spun out of CEO and co-founder Evan Feinberg’s breakthrough artificial Intelligence (AI) research at Stanford University’s Pande Lab , Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs. which will remain a key shareholder.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

Delveinsight

JANUARY 12, 2021

The companies believe that their candidate in its original IgG format has shown potent neutralization activity in in vitro assays and in an in vivo animal model. Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor cells.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

Delveinsight

JANUARY 18, 2021

Preclinical studies undertaken to evaluate the drug have shown that GTX-102 activates the paternal copy of the UBE3A gene in neurons in vitro, and can ease certain disease symptoms in a mouse model of Angelman syndrome. Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system.

Marketing 52

Marketing Gene Drugs Protein 52

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

The Pharma Data

OCTOBER 21, 2020

Research s howed KB-0742 i nhibited a ndrogen r eceptor -d ependent a ctivity and r educed t umor g rowth in c astration -r esistant p rostate c ancer. KB-0742 is a transcription regulatory network modulator discovered using the company’s proprietary high – throughput screening platform. SAN MATEO, Calif., and CAMBRIDGE, Mass.,

In-Vivo 40

In-Vivo In-Vitro Bioavailability Clinical Trials 40

The Pharma Data

JANUARY 11, 2021

Our antibody clones in their original IgG format have shown potent neutralization activity in in vitro assays and, in the case of our lead clone, in an in vivo animal model. Upon binding, the antibodies block the spike protein from interacting with ACE2 and thereby prevent virus-induced cell-killing, also known as cytopathic effect.

Antibody 52

Antibody Licensing Licensing Development 52

FDA Law Blog

OCTOBER 11, 2022

Valentine — As we begin the final quarter of 2022 and the leaves here on the east coast begin to turn and fall, it seems the clock may be running out on FDA and the Center for Drug Evaluation and Research (CDER) to meet its goal of publishing a draft guidance on confirmatory evidence this year.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Trials 61

The Pharma Data

OCTOBER 22, 2020

Previously authorized by the FDA for emergency use to treat COVID-19, Veklury is now the first and only approved COVID-19 treatment in the United States. The drug is now widely available in hospitals across the country, following early investments to rapidly expand manufacturing capacity to increase supply.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

XTalks

OCTOBER 1, 2020

WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. Motivations for Transition. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

Roots Analysis

OCTOBER 19, 2023

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ). These are mainly transmitted through air, water, living organisms, and food.

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

Pharmaceutical Technology

FEBRUARY 28, 2023

The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials. It also activated tumour-infiltrating DCs and T cells in vivo pharmacodynamic studies. Early R&D projects coverage on Pharmaceutical Technology is supported by Mimotopes.

In-Vivo 130

In-Vivo Antibody In-Vitro Licensing 130

The Pharma Data

NOVEMBER 17, 2020

. SARASOTA, Fla. , 18, 2020 /PRNewswire/ — INVO Bioscience , Inc. Hammond , DNP, CRNP, IVF Program Director of the America Institute of Reproductive Medicine in Birmingham, Alabama ; and. Drs. and across the world. Amber R.

In-Vivo 52

In-Vivo In-Vitro Genetics Doctor 52